Recombinant Rotavirus (RV-A), VP6

Recombinant Rotavirus (RV-A), VP6

Product No.: R341

- -
- -
Alternate Names
Rotavirus VP6, VP6
Product Type
Recombinant Protein
Expression Host
HEK-293 Cells
Applications
ELISA
Lateral Flow
WB

- -
- -
Select Product Size
- -
- -

Background

Rotaviruses are non-enveloped viruses of the Reoviridae family that feature a capsid composed of structural proteins (VP1-VP4 and VP6-VP7) as well as non-structural proteins (NSP1-NSP5/6)1. VP6 is used for classifying the RV type, and based on its serological cross-reactivity and genetic variability, ten groups (RVA-RVJ) have been established as well as four subgroups (SGI, II, I+II, and non-I, non-II). Of these, group A rotavirus (RVA) is the leading cause of acute gastroenteritis in children under five.

VP6 protein is highly abundant, conserved, antigenic, and immunogenic1. Functionally, VP6 is the structural protein that forms the middle capsid layer that surrounds the core shell of RV1. It assembles as 260 trimers with a T=13 I icosahedral lattice and has the ability to interact with itself, VP2, VP4, and VP7. Assembly of trimeric VP6 occurs spontaneously, and oligomer formation is an intrinsic property of the protein. VP6 produced by in vitro expression systems form trimers ordered into hexagons, and can form nanospheres, nanotubes, and sheets depending on pH and ionic strength.

VP6 protein has been identified as a new generation RV vaccine candidate1. VP6 DNA vaccines, VP6 proteins, and self-assembled VP6 all induce a response and/or protection in mice challenged with RV. VP6 is also the basis of a rapid nanobody-based ELISA able to identify RVA in feces from pediatric patients1.

Protein Details

Species
Viral
Format
Purified No Carrier Protein
Protein Accession No.
B2BN53
Amino Acid Sequence
RTGFTFHKPNIFPYSASFTLNRSQPAHDNLMGTMWLNAGSEIQVAGFDYSCAINAPANIQQFEHIVQLRRVLTTATITLLPDAERFSFPRVINSADGAaTWYFNPVILRPNNVEVEFLLNGQIINTYQARFGTIIARNFDTIRLSFQLMRPPNMTPAVAALFPNAQPFEHHATVGLTLRIESAVCESVLADAS
State of Matter
Lyophilized
SDS-Page Molecular Weight
~50k
Predicted Molecular Mass
~66k
Reconstitution
Reconstitute at 0.1-1 mg/ml using filtered deionized water. Gently mix by vortexing and/or inversion until fully dissolved. Centrifuge if necessary.
Storage and Stability
1 month, 2 to 8 °C under sterile conditions after opening.
1 year from date of receipt, -20 to -80 °C sterile conditions after opening. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Frozen Dry Ice
Ligand/Receptor
VP6
Species
Viral
Regulatory Status
Research Use Only
NCBI Gene Bank
UniProt.org
Applications and Recommended Usage ?
(Quality Tested by Leinco)
Lateral Flow,
WB,
ELISA

References & Citations

1 Afchangi A, Jalilvand S, Mohajel N, et al. Rev Med Virol. 29(2):e2027. 2019.
2 Vega CG, Garaicoechea LL, Degiuseppe JI, et al. J Virol Methods. 298:114279. 2021.
Indirect ELISA Protocol
Lateral Flow
General Western Blot Protocol

Certificate of Analysis

IMPORTANT Use lot specific datasheet for all technical information pertaining to this recombinant protein.
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.